Helen Varker, BS

Articles

December 23rd 2020

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD

We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

December 23rd 2020

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD

Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

December 23rd 2020

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD

This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

December 23rd 2020

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.